Medicine Symposium No. 8-Drug Preclinical Research and Application

Over the years, Medicilon has been actively empowering the upgrading of life sciences and building a platform to promote the integrated development of the biomedical industry. In 2019, starting from the 15th anniversary, a national tour of seminars was launched, and seven pre-clinical research related seminars were successively held. The Medicilon research team shared the rich knowledge and points in the preclinical one-stop research process. Case cooperation experience has attracted thousands of R&D colleagues to participate in registration, providing participants with a platform for learning and communication.
An unprecedented change in the international situation in 2020 will also affect the pharmaceutical industry. Under the epidemic situation, there are challenges and opportunities. The development of drugs and the process of innovative drugs have attracted much attention and investment from the country and the pharmaceutical industry. How to improve preclinical research capabilities, increase innovation efficiency, and successfully achieve IND registration is a common topic for companies active in preclinical new drug research and development.
In recent years, 91 new drug and generic drug projects that the company has participated in research and development have been approved by CFDA/NMPA/US FDA/Australia TGA/Sweden EMA to enter clinical trials. Medicilon continues to absorb, improve, and innovate and iterate on new drug R&D technologies. In order to share the accumulated experience with new drug research and development colleagues in a timely manner, in October 2020, Medicilon re-launched and invited research experts Dr. Shuangqing Peng and Dr. Wenxin Dong from preclinical research institutions , Walk into the biomedical industry park, share and discuss popular topics such as innovative drug research and development, preclinical  pharmacology evaluation, IND application, etc., and discuss with you the challenges and coping strategies faced by drug preclinical research. Looking forward to your presence!

Activity Details

Time: 13:30-17:00, October 22, 2020
Location: Chengdu Tianfu Life Science Park Management Building
Organizer: Shanghai Medicilon Biopharmaceutical Co., Ltd.
             Chengdu Gaotou Biomedical Park Management Co., Ltd.
Meeting schedule
13:00-13:20
—- Sign in
13:20-13:30
—- Opening speech
—- Ms. Jinna Cai, Vice President of Medicilon Business Development
13:30-14:10
—- Pitfalls and countermeasures of preclinical research and development of small molecule chemicals
—- Dr. Feng Ren, Senior Vice President of the Chemistry and Biology Department of Medicilon
14:10-14:50
—- Discovery of a new generation of anti-drug resistant BTK inhibitors
—- Dr. Yingfu Li, President of Chengdu Haibo Pharmaceutical Co., Ltd.
14:50-15:10
—- tea break
15:10-15:50
—- Pre-clinical efficacy evaluation system and R&D strategy
—- Dr. Wenxin Dong, Executive Director of Medicilon
15:50-16:30
—-Innovative drug preclinical safety evaluation IND application requirements and concerns
—- Dr. Shuangqing Peng, Chief Scientific Officer of Medicilon
16:30-17:00
—- Free communication

Event Guests (in order of speech)

Both bachelor, master and doctorate graduated from China Pharmaceutical University, and then worked in the post-doctoral mobile station of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He has more than 20 years of experience in the development and research of new Chinese medicines and chemical products. Dr. Cai was awarded the first prize for scientific and technological progress of the State Administration of Traditional Chinese Medicine in 1991 and the first prize of scientific and technological progress for 1992. Later, he served as the director of the research center in the R&D department of Huiren Group. He was responsible for organizing and coordinating the development of 5 new drugs and chemical drugs of category 3.1 new drug products and the development and research of 5 new drugs of Chinese medicine injections. At the same time, he was also responsible for organizing and coordinating more than 40 Chinese medicines and chemical drugs Most of the research and application of the species have obtained clinical approval or production approval. At the same time, she was awarded the “Top Ten” Female Employees of Huiren Company in 2004 and was named “Tenth Five-Year” Provincial Enterprise Technology Center Management Advanced Individual by Jiangxi Provincial Economic and Trade Commission in 2006.

In 2007, he graduated from the Department of Chemistry, Harvard University, USA. 11 years of experience in the research and development of small molecule innovative drugs by a multinational pharmaceutical company (GSK). Served as the chief researcher, deputy director, director, and head of the chemistry department of GlaxoSmithKline’s R&D department. Successfully developed several clinical candidate compounds/clinical phase I compounds for the treatment of Parkinson’s disease, multiple sclerosis, ankylosing spondylitis, and pain. In 2018, he joined Medicilon as the vice president, responsible for the R&D service business of the Chemistry Department and Biology Department.

Sichuan Thousand Talents Plan expert, Rongpiao Plan expert, Deputy Director of the Biomedicine Committee of Chengdu Talent Development Promotion Association, and member of Chengdu CPPCC. Dr. Yingfu Li has served as senior researcher, senior project supervisor, senior research scientist, and senior project supervisor in Bayer’s German Pharmaceutical Research Center, Japan Research Center, American Research Center, and AMRI Global, the largest pharmaceutical CRO company in the United States. After returning to China in 2009, he successively served as chief scientific officer, vice president, general manager of Chengdu branch, and dean of the Institute of Pharmaceutical Research in Yangtze River Pharmaceutical, Ruizhi Chemical, Chengdu Better Pharmaceutical and other companies. In January 2019, he founded hyperwaypharma in Chengdu High-tech Zone and served as President. Dr. Yingfu Li is an expert in the field of new drug research and development with an international vision. He specializes in the research and development of anti-cancer drugs, anti-infective drugs, and respiratory disease drugs. He has participated in the research and development of dozens of generic drugs and innovative drugs, and is the first inventor and project chief of multiple clinical drug candidates, many of which have become pillar research and development products.

From 1991 to 1997, he went to study at the Six Medical Schools of Paris and the French National Academy of Medical Sciences, and obtained a master’s degree and a doctorate degree in pharmacology. He was a researcher and doctoral supervisor of the Shanghai Institute of Pharmaceutical Industry, a director of the Shanghai Pharmaceutical Association, and a vice Chairman, recipient of special allowance from the State Council. He has been engaged in pharmacological research and new drug research and development for a long time, mainly in the fields of cardio-cerebrovascular system and neuropsychiatric pharmacology. He has undertaken a number of national and municipal major new drug innovation projects. He presided over the establishment of the technological platform for the development of new antidepressant and anti-Alzheimer’s drugs pharmacological effects, and established a new analgesic drug, anti-anxiety new drug, and new anti-Parkinson’s disease drug R&D technology platform. Responsible for completing pre-clinical research tasks for dozens of new drugs.

Researcher and doctoral supervisor of the Academy of Military Medical Sciences. Served as the vice chairman of the Chinese Society of Toxicology and the executive director of the Chinese Society of Environmental Mutagens. Long engaged in the safety evaluation of innovative drugs and GLP management, undertaking the construction of the national GLP technology platform supported by the Ministry of Science and Technology, presided over and undertook more than 40 national scientific research projects, including the 973 project, the 863 plan project and the national “Major new drug creation” science and technology project . Published more than 280 scientific research papers, including more than 100 SCI academic papers, and edited (participated) 12 monographs. Twelve scientific and technological achievements have won national, provincial and ministerial achievement awards. He has won the special government allowance of the State Council, the post allowance of outstanding military personnel, the honorary title of “Outstanding Scientific and Technological Worker” of the Chinese Association for Science and Technology, and the Outstanding Contribution Award of the Chinese Society of Toxicology. Guided the training of more than 90 master, doctoral and postdoctoral students. Is a new drug review expert of the State Food and Drug Administration.